SCHEMBL7749694

SCHEMBL7749694

CCOCCNC(=O)OCc1ccccc1

nearest known ligand 0.82

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.82
LMNA P02545 1/20 0.82
L3MBTL1 Q9Y468 2/20 0.65
MAPT P10636 1/20 0.65
HTT P42858 2/20 0.60
TGM2 P21980 1/20 0.53
KEAP1 Q14145 2/20 0.52
NFE2L2 Q16236 2/20 0.52
SLC1A3 P43003 1/20 0.50
SLC1A1 P43005 1/20 0.50
CTSL P07711 1/20 0.50
CTSB P07858 1/20 0.50
CTSS P25774 1/20 0.50
CTSK P43235 1/20 0.50
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49
HDAC3 O15379 1/20 0.49
HDAC4 P56524 1/20 0.49
HDAC1 Q13547 1/20 0.49
HDAC7 Q8WUI4 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30229351 0.97 SMN1; SMN2 (0.83) SMN1; SMN2LMNAL3MBTL1MAPTHTT
SCHEMBL7372302 0.91 SMN1; SMN2 (1.00) SMN1; SMN2LMNAL3MBTL1MAPTHTT
SCHEMBL16302062 0.90 SMN1; SMN2 (0.85) SMN1; SMN2LMNAL3MBTL1MAPTHTT
SCHEMBL30823376 0.89 SMN1; SMN2 (0.97) SMN1; SMN2LMNAL3MBTL1MAPTHTT
SCHEMBL15164979 0.88 SMN1; SMN2 (0.83) SMN1; SMN2LMNAL3MBTL1MAPTHTT
SCHEMBL29399108 0.88 SMN1; SMN2 (0.83) SMN1; SMN2LMNAL3MBTL1MAPTHTT
SCHEMBL24991324 0.87 LMNA (0.81) SMN1; SMN2LMNAL3MBTL1MAPTHTT
SCHEMBL18594580 0.85 SMN1; SMN2 (0.83) SMN1; SMN2LMNAL3MBTL1MAPTHTT
SCHEMBL7289871 0.85 SMN1; SMN2 (0.78) SMN1; SMN2LMNAL3MBTL1MAPTHTT
SCHEMBL20526178 0.85 SMN1; SMN2 (0.72) SMN1; SMN2LMNAL3MBTL1MAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0622361-B1 Heterocyclic compounds as bradykinin antagonists FUJISAWA PHARMACEUTICAL CO (JP) 2001-10-04 EP disclosed
US-6169095-B1 FOR PREVENTION AND/OR TREATMENT OF BRADYKININ OR ITS ANALOGUES MEDIATED DISEASES IN THE EYE, SUCH AS ALLERGY, INFLAMMATION AND PAIN OF THE EYE FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-01-02 US disclosed
US-5922711-A ANTIALLERGENS, ANTIINFLAMMATORY AGENTS, AUTOIMMUNE DISEASES, SHOCK OR ANALGESICS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1999-07-13 US disclosed
US-5708173-A PREPARATION OF SUBSTITUTED QUINOLINE COMPOUNDS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1998-01-13 US disclosed
US-5563162-A CAN BE ADMINISTERD FOR THE TREATMENT OF ALLERGY, INFLAMMATION, AUTOIMMUNE DISEASES, SHOCK OR PAIN IN ANIMALS AND HUMANS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1996-10-08 US disclosed
EP-0622361-A1 Heterocyclic compounds as bradykinin antagonists FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1994-11-02 EP disclosed